The Zinbryta market withdrawal has recently become active after the manufacturers determined that the serious risk of side effects posed problems for those patients taking this MS medication. Many of the reasons behind the Zinbryta market withdrawal include complaints from patients about the development of Stevens-Johnson Syndrome, liver failure, or encephalitis.

The Zinbryta market withdrawal came about after numerous patients came forward with complaints and the manufacturers AbbVie and Biogen announced in March 2018 that they would voluntarily withdraw the drug from the global market.

Some of the most common reported side effects that prompted the Zinbryta market withdrawal included inflammatory brain disorders, such as encephalitis.

At least 12 cases of encephalitis associated with the use of Zinbryta have been recorded around the world, and three of those cases have had fatal complications. Zinbryta market withdrawal was also spurred by consumer adverse event reports associated with serious skin reactions and liver failure.

Zinbryta’s History on the Market

In May 2016, the FDA provided initial approval of Zinbryta for those adults who were suffering from relapsing forms of multiple sclerosis. Typically, this medication is only given to those multiple sclerosis patients who have had a negative or inadequate response to two or more other types of MS drugs.

Problems with serious Zinbryta side effects ultimately were reported in the form of complaints from patients beginning as soon as the drug was brought to market. Some of the most common complications include liver injury and liver failure, immune reactions, skin reactions, and more. The FDA has already indicated that they were aware of the complex safety profile associated with this medication as soon as it was approved.

When drug manufacturers receive multiple reports of serious side effects and problems, they may opt to remove the drug from the market on their own. This may be done in conjunction with the FDA’s support so that the medical community and patients know how the process will work.

AbbVie and Biogen decided to carry out a Zinbryta market withdrawal after the deaths in reported cases around the world. Encephalitis symptoms may last for up to three weeks and may grow progressively worse if they are not captured by a medical professional immediately. Some individuals who have developed encephalitis may have no symptoms at all, but the most common side effects include seizures, fatigue, headache, fever, muscle weakness, irritability, sensitivity to light, vomiting, disorientation, nausea, stiff neck and more.

The FDA is working directly with the manufacturers to support the Zinbryta market withdrawal, and no new patients will begin taking the medication or participating in clinical studies. The drug remained available for those patients who may have needed it through April 30, 2018.

The voluntary Zinbryta market withdrawal may have important ramifications for those who have been taking this MS medication. Many of those consumers who have already suffered these side effects have chosen to participate in class action lawsuit investigations. If you or someone close to you have been injured as a result of Zinbryta, you may be eligible to participate in a free lawsuit investigation.